Ipilimumab
Tumors Metastatic to Brain
Ohio State University Comprehensive Cancer Centermonoclonal_antibodyPhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Tumors Metastatic to Brain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Etirinotecan Pegol Joel Neal | Phase 2 | B |
METHOTREXATE University of Washington | Phase 2 | B |
Thalidomide National Cancer Institute (NCI) | Phase 2 | B |
Cytosin-Arabinosid University of Washington | Phase 2 | B |
Lapatinib National Cancer Institute (NCI) | Phase 2 | CCC |
Cediranib City of Hope Medical Center | Phase 1 | CC |
Bafetinib City of Hope Medical Center | Phase 1 | CC |
VEMURAFENIB | Phase 1 | CC |
Same molecule, other indications
Ipilimumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →